Skip to main content
SpringerLink
Log in

Switching from PCV10 to PCV13 cost effective in Colombia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. gross domestic product

  2. 2014 US dollars

Reference

  • Castaneda-Orjuela C, et al. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine : 4 Aug 2018. Available from: URL: http://doi.org/10.1016/j.vaccine.2018.07.078

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Switching from PCV10 to PCV13 cost effective in Colombia. PharmacoEcon Outcomes News 810, 31 (2018). https://doi.org/10.1007/s40274-018-5222-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5222-6

Search

Navigation